Johnson & Johnson (JNJ.US) plans to spend $3.4 billion to acquire Ollin, expanding its presence in the retinal disease treatment sector.
According to sources familiar with the matter, Johnson & Johnson may announce a deal as early as Monday to acquire Texas-based biotech company Ollin Biosciences for up to $3.4 billion.
According to English financial media Zhitong Finance APP, sources reveal that Johnson & Johnson (JNJ.US) may announce a deal as early as Monday to acquire Texas-based biotech company Ollin Biosciences for up to $3.4 billion. According to reports, under the terms currently being discussed, Johnson & Johnson may pay $2.2 billion in cash as an upfront payment to Ollin's investors, with an additional milestone payment of up to $1.2 billion. However, the ongoing negotiations still have the possibility of falling through, and the deal has not been officially confirmed by either party.
The core asset in this acquisition is the ophthalmic drug OLN324, currently under development by Ollin. OLN324 is a next-generation VEGF/Ang2 bispecific antibody designed to treat diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). Both of these retinal diseases are key causes of severe vision loss. If the deal proceeds, Johnson & Johnson would further extend its reach in the field of retinal disease treatment. Although Johnson & Johnson runs a contact lens business, its presence in the retinal disease drug market is relatively limited.
In June this year, Ollin announced the completion of an oversubscribed $330 million Series B round led jointly by TCGX and ARCH Venture Partners. Other participating investors include a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, and T. Rowe Price Investment Management. Ollin stated that these funds will primarily support the global phase III clinical trials of OLN324 in diabetic macular edema and wet age-related macular degeneration, as well as advance another candidate, OLN102, into clinical development phases.
Notably, OLN324 has already been compared against Roche’s ophthalmology drug Vabysmo (faricimab) in a randomized, head-to-head proof-of-concept study. According to data released by Ollin, the JADE clinical study involving 164 patients showed that OLN324 demonstrated a faster and more significant improvement in retinal anatomy than Vabysmo, as well as a numerically greater improvement in visual acuity for both diabetic macular edema and wet age-related macular degeneration indications.
Ollin stated that the company has completed the end-of-phase II clinical trial meeting with the U.S. Food and Drug Administration (FDA) and has received scientific advice from the European Medicines Agency (EMA) regarding its phase III clinical plans, with global phase III trials of OLN324 targeting these two indications planned for launch in the second half of 2026. Ollin also estimates the retinal disease treatment market size at $15 billion and believes OLN324 could offer a differentiated competitive edge in this market. However, the drug is still in clinical development, and its efficacy, safety, and commercial potential await further validation from subsequent clinical trials.
In addition to OLN324, Ollin is also developing another bispecific antibody candidate, OLN102, targeting thyroid stimulating hormone receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R), intended for the treatment of thyroid eye disease (TED) and Graves’ disease. Should Johnson & Johnson complete the acquisition of Ollin, in addition to acquiring OLN324 as a major clinical asset, it will also obtain Ollin’s early-stage R&D pipeline.
This potential deal also reflects Johnson & Johnson’s ongoing strategy of supplementing its innovative drug R&D pipeline through acquisitions. In June this year, Johnson & Johnson announced a $1 billion cash acquisition of biotech company Firefly Bio, with the deal closing in July. Firefly Bio owns a proprietary Degrader Antibody Conjugate (DAC) platform called Firelink, focusing on broad KRAS and other hard-to-treat cancer targets, aiming to develop targeted therapies for KRAS-driven tumors and other solid tumors. Johnson & Johnson stated that this acquisition will enhance its next-generation antibody engineering capabilities and expand its oncology drug R&D portfolio.
In 2025, Johnson & Johnson also completed a roughly $14.6 billion acquisition of pharmaceutical company Intra-Cellular Therapies to strengthen its portfolio in the central nervous system disease treatment arena. This acquisition brought Johnson & Johnson the core drug CAPLYTA (lumateperone), which has received FDA approval for the treatment of adult schizophrenia as well as monotherapy and adjunctive therapy for bipolar I and II depression. In addition, Intra-Cellular Therapies holds clinical-stage R&D programs targeting generalized anxiety disorder, Alzheimer’s disease-related psychosis and agitation, among other areas.
From an industry perspective, M&A activity among biotech firms has also been quite active this year. According to data from investment bank Stifel, 46 biotech companies with deal values over $1 billion have been acquired so far this year, surpassing last year’s record of 35. If the Johnson & Johnson and Ollin transaction is finalized, it will represent another major deal in this ongoing wave of biotech industry acquisitions.
For Johnson & Johnson, acquiring Ollin not only adds a late-stage ophthalmology candidate to its pipeline, but also presents an opportunity to enter the high-potential retinal disease treatment segment. However, OLN324 will still need to prove its advantage over existing therapies through global phase III clinical trials, and the ultimate value of the transaction will depend on further clinical progress and the realization of potential milestone payments.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BoJ’s Takata calls for nimble, data-dependent rate hikes rather than a fixed pace
AI Infrastructure Stocks Shed $4.2 Trillion—Is the “Shovel Seller Feast” Over?
Since June, Caterpillar has dropped by 44%, and Oklo has plummeted by 49%. Analysts point to the root cause: investors have been speculating on traditional industrial stocks as growth stocks, resulting in severely overvalued prices. Another key factor behind the sell-off is the uncertainty of data center regulatory policies following the U.S. midterm elections. The fundamentals remain resilient—Caterpillar has a backlog of orders totaling $78 billion, and several companies have secured revenue growth through 2027.

As market forces battle each other, the yen is caught in a tug-of-war between bulls and bears! Goldman Sachs bets on a comeback while Morgan Stanley predicts a fall to 162
As the USD/JPY exchange rate approaches the key 160 level again, Morgan Stanley and Goldman Sachs have expressed sharply divergent views on the yen’s outlook. This highlights that forecasting the yen’s exchange rate is becoming increasingly challenging amid multiple conflicting forces.

Morgan Stanley MUFG Securities: Four Major Tailwinds Support Japanese Stocks, Raising TOPIX Target to 4,800 Points
Morgan Stanley MUFG Securities maintains an overweight position in Japanese stocks globally and sets the TOPIX benchmark target at 4,800 points by the end of 2027.

